EMAIL THIS PAGE TO A FRIEND

International journal of nanomedicine

Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.


PMID 25075187

Abstract

Colon cancer is the third most common cancer and the third largest cause of cancer-related death. Fluorouracil (5-FU) is the front-line chemotherapeutic agent for colon cancer. However, its response rate is less than 60%, even in combination with other chemotherapeutic agents. The side effects of 5-FU also limit its application. Nanoparticles have been used to deliver 5-FU, to increase its effectiveness and reduce side effects. Another common approach for colon cancer treatment is targeted therapy against the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway. A recently-invented inhibitor of this pathway, BEZ-235, has been tested in several clinical trials and has shown effectiveness and low side effects. Thus, it is a very promising drug for colon cancer treatment. The combination of these two drugs, especially nanoparticle-packed 5-FU and BEZ-235, has not been studied. In the present study, we demonstrated that nanoparticles of layered double hydroxide (LDH) loaded with 5-FU were more effective than a free drug at inhibiting colon cancer cell growth, and that a combination treatment with BEZ-235 further increased the sensitivity of colon cancer cells to the treatment of LDH-packed 5-FU (LDH-5-FU). BEZ-235 alone can decrease colon cancer HCT-116 cell viability to 46% of the control, and the addition of LDH-5-FU produced a greater effect, reducing cell survival to 8% of the control. Our data indicate that the combination therapy of nanodelivered 5-FU with a PI3K/Akt inhibitor, BEZ-235, may promise a more effective approach for colon cancer treatment.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

F6627
5-Fluorouracil, ≥99% (HPLC), powder
C4H3FN2O2
03738
5-Fluorouracil, analytical standard
C4H3FN2O2
858471
5-Fluorouracil, 99%
C4H3FN2O2
03382
Aluminum atomic spectroscopy standard concentrate 10.00 g Al, 10.00 g/L, for 1 l standard solution, analytical standard
AlCl3
563919
Aluminum chloride, anhydrous, powder, 99.999% trace metals basis
AlCl3
294713
Aluminum chloride, 99.99% trace metals basis
AlCl3
449598
Aluminum chloride, anhydrous, powder, 99.99% trace metals basis
AlCl3
495352
Aluminum chloride, ReagentPlus®, anhydrous, ≥99.9% trace metals basis
AlCl3
06230
Aluminum chloride, purum, anhydrous, ≥98.0% (AT)
AlCl3
11019
Aluminum chloride, anhydrous, sublimed, ≥98%
AlCl3
249882
Aluminum chloride solution, 1.0 M in nitrobenzene
AlCl3
06154
Aluminum standard for AAS, analytical standard, traceable to BAM
AlCl3
F8423
Fluorouracil, meets USP testing specifications
C4H3FN2O2
PHR1227
Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
C4H3FN2O2
F0250000
Fluorouracil, European Pharmacopoeia (EP) Reference Standard
C4H3FN2O2
1279000
Fluorouracil, United States Pharmacopeia (USP) Reference Standard
C4H3FN2O2
43617
Sodium hydroxide concentrate, 0.1 M NaOH in water (0.1N), Eluent concentrate for IC
HNaO
72064
Sodium hydroxide solution, 50-52% in water, eluent for IC
HNaO
72071
Sodium hydroxide solution, for the determination of nitrogen, ≥32.0% in H2O (T)
HNaO